RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

BTG's sleep apnea treatment combines two serotonergic agents (which they have not specifically disclosed), which raises some combo problems. Galleon Pharma is a competitor, but their compound has some potential cardiac issues. The company I have been surprised by is Sanofi-Aventis, which has a couple of compounds in the clinic, one in Phase II, one in Phase I. A potentially powerful competitor, but the fact that a major pharma is putting effort into sleep apnea means that others will follow--because Big Pharmas are like sheep--not all--but if one defines a market as important, some others will decide that they should too. But they will go where some risk has been eliminated, and until CX1739 shows POC, the big risk is--that it doesn't work. If and when Cortex moves past that risk, the dynamic will change.

NeuroInvestment